Case Report
Pathologic diagnosis of large cell neuroendocrine carcinoma of the lung in an axillary lymph node: a case report with immunohistochemical and molecular genetic studies

Tadashi Terada

Department of Pathology, Shizuoka City Shimizu Hospital, Shimizu, Shizuoka, Japan

Received September 23, 2012; Accepted March 27, 2013; Epub May 15, 2013; Published June 1, 2013

Abstract: The author herein reports a large cell neuroendocrine carcinoma (LCNEC) of the lung diagnosed in an axillary lymph node without clinical data, with an emphasis of KIT and PDGFRA. A 64-year-old woman presented with axillary and cervical lymph nodes swelling. An excisional biopsy of an axillary lymph node was performed under the clinical diagnosis of malignant lymphoma. The HE section showed a presence of large malignant cells arranged in a medullary pattern. The tumor cells had nucleoli. The HE diagnosis was large cell lymphoma or metastatic undifferentiated carcinoma, in particular large cell carcinoma of the lung. Therefore, immunohistochemical study was performed by Dako’s Envision method [1]. The tumor cells were positive for cytokeratins (AE1/3 and polyclonal wide, Dako Corp., Glostrup, Denmark), p53 (almost 100%) (Dako), thyroid transcriptional factor-1, neuron-specific enolase, synaptophysin, CD56, KIT, and PDGFRA. In contrast, they were negative for CD3, CD15, CD30, CD45, CD20, CD45RO, CEA, CA19-9, and chromogranin (Dako). Ki-67 labeling (Dako) was 100%. Therefore, a diagnosis of LCNEC of the lung was made. A molecular genetic analysis for KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 12 and 18) identified no mutations. Later, a lung tumor and pleural effusion were detected, and the cytology of the effusion and sputum revealed carcinoma cells compatible with LCNEC. The patient was diagnosed as lung LCNEC, and treated by chemotherapy (cisplatin) and radiation (45 Gray). The present report is the first one with an examination of protein expression and gene mutations of KIT and PDGFRA in a metastatic focus of LCNEC of the lung.

Keywords: LCNEC, KIT, PDGFRA, metastasis

Introduction

Large cell neuroendocrine carcinoma (LCNEC) of the lung is high grade neuroendocrine carcinoma composed of large cells. LCNEC shows features common to small cell carcinoma, and characterized by positive reaction to KIT in addition to positive neuroendocrine markers. The author herein reports an LCNEC of the lung diagnosed in an axillary lymph node without clinical data.

Case report

A 64-year-old woman presented with axillary and cervical lymph nodes swelling. An excisional biopsy of an axillary lymph node was performed under the clinical diagnosis of malignant lymphoma. The HE section showed a presence of relatively large malignant cells arranged in a medullary pattern (Figure 1A). The tumor cells had nucleoli, and cell adhesion was not clear. The HE diagnosis was large cell lymphoma or metastatic undifferentiated carcinoma, in particular large cell carcinoma of the lung. Therefore, an immunohistochemical study was performed by Dako’s Envision method [1]. The tumor cells were positive for cytokeratins (AE1/3 and polyclonal wide, Dako Corp., Glostrup, Denmark), p53 (almost 100%) (Dako), thyroid transcriptional factor-1 (TTF-1) (Dako) (Figure 1B), neuron-specific enolase (Dako), synaptophysin (Dako) (Figure 1C), CD56 (Dako) (Figure 1D), KIT (Dako) (Figure 1E), and PDGFRA (Santa Cruz, CA, USA) (Figure 1F). In contrast, they were negative for CD3 (Dako), CD15 (Dako), CD30 (Dako), CD45 (Dako), CD20 (Dako), CD45R0 (Dako), CEA (Dako), CA19-9 (TFB, Yokohama Japan), and chromogranin (Dako).
Neuroendocrine carcinoma of lung in axillary lymph node

Ki-67 labeling (Dako) was 100%. Therefore, a diagnosis of LCNEC of the lung was made.

A molecular genetic analysis for KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 12 and 18) genes was performed, in paraffin specimens, by the PCR-direct sequencing method, as previously described [2-5]. The analysis identified no mutations of the KIT and PDGFRA genes.

During the pathologic study, imaging modalities were performed and showed a right lung tumor, its metastases to mediastinal lymph nodes, and right pleural effusion. The author did not
Neuroendocrine carcinoma of lung in axillary lymph node

know these clinical findings. The cytology of the pleural effusion and sputum revealed carcinoma cells compatible with LCNEC. Lung biopsy was not performed. The patient was treated by chemotherapy (cisplatin) and radiation (45 Gray).

Discussion

LCNEC is relatively rare tumor with aggressive characters, like small cell lung carcinoma (SCLC). LCNEC and SCLC are neuroendocrine malignancies of the lungs. The differences between them are cell size and cell morphologies. The present case showed apparent neuroendocrine features, and cell morphologies were those of LCNEC. It is unique that the diagnosis of LCNEC of the lung was made by pathologic examinations of one lymph node without knowledge of clinical data in the present case.

KIT protein is frequently expressed in SCLC [6, 7] and LCNEC [8-10], as in the present case. Rossi et al. [8] reported that KIT protein was expressed in 63% of LCNEC of the lung. Sihto et al [6] reported that 30% of SCLC expressed KIT protein. KIT mutations are extremely rare in SCLC [6, 7]. Rossi et al [8] found no mutations in exons 9 and 11 of KIT gene in 83 patients with LCNEC. In the present case, KIT mutations in exons 9, 11, 13 and 17 were not present.

Although there have been no reports of PDGFRA protein expression in SCLC to the author’s best knowledge, Sihto et al. [6] reported no PDGFRA mutations in 30 SCLCs. Rossi et al. [8] reported that PDGFRA expression was found in 80% of LCNEC of the lung. PDGFRA expression was seen in the present case. Sihto et al. [6] reported that no PDGFRA mutations were identified in 30 SCLCs. Rossi et al. [8] found no mutations in exons 12 of PDGFRA gene in 83 patients with LCNEC. In the present case, PDGFRA mutations in exons 12 and 18 were not present.

In summary, the author reported a rare case of LCNEC of the lung diagnosed in an axillary lymph node without knowledge of clinical data. The present LCNEC of the lung expressed KIT and PDGFRA proteins but were free of KIT and PDGFRA gene mutations.

Declaration

The author declares no conflict of interest.

Address correspondence to: Dr. Tadashi Terada, Department of Pathology, Shizuoka City Shimizu Hospital, Miyakami 1231 Shimizu-Ku, Shizuoka 424-8636, Japan. Tel: 81-54-336-1111; Fax: 81-54-336-1315; E-mail: piyo0111jp@yahoo.co.jp

References